AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17309590 — intervention group
Group type: COMPARATOR
Intervention: Quadrant wise scaling and root planing (QRP)
Number of subjects: 20
Study 16078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel sonography in neonates with NEC (n = 40)
Number of subjects: 40
Study 16078076 — intervention group
Group type: COMPARATOR
Intervention: Bowel sonography in healthy neonates (control group, n = 10)
Number of subjects: 40
Study 16078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examinations in NEC patients (n = 40)
Number of subjects: 40
Study 16078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of NPO in group I (echogenic dots)
Number of subjects: 40
Study 16078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of NPO in group II (dense granular echogenicities)
Number of subjects: 40
Study 12194067 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coherence laser interferometry (PCLI)
Number of subjects: 100
Study 12194067 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound biometry
Number of subjects: 100
Study 9535301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 129
Study 9535301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 129
Study 7808251 — intervention group
Group type: EXPERIMENTAL
Intervention: No-rest group (performed repeated lifts without resting)
Number of subjects: 42
Study 7808251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest group (rested for 30 s between lifts)
Number of subjects: 42
Study 7808251 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not train)
Number of subjects: 42
Study 2520624 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of 40 mg famotidine
Number of subjects: 118
Study 2520624 — intervention group
Group type: COMPARATOR
Intervention: Bedtime dose of 40 mg famotidine
Number of subjects: 118
Study 2520624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and bedtime doses of famotidine
Number of subjects: 118
Study 4741605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started within two months of operation
Number of subjects: 114
Study 4741605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started three years after oophorectomy
Number of subjects: 114
Study 4741605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started six years after oophorectomy
Number of subjects: 114
Study 28976781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use (≥4 months)
Number of subjects: 250
Study 28976781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pacifier use)
Number of subjects: 250
Study 28724351 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention (PTN)
Number of subjects: 80
Study 28724351 — intervention group
Group type: COMPARATOR
Intervention: Social support (SOSU)
Number of subjects: 80
Study 26141511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 100
Study 26141511 — intervention group
Group type: COMPARATOR
Intervention: Placebo acamprosate
Number of subjects: 100
Study 24104936 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 247
Study 24104936 — intervention group
Group type: COMPARATOR
Intervention: Systemic cyclosporine
Number of subjects: 247
Study 24104936 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic tacrolimus
Number of subjects: 247
Study 24104936 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids or cyclosporine
Number of subjects: 247
Study 22403975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) + 0.05% sodium fluoride (NaF) in a 6% alcohol base
Number of subjects: 188
Study 22403975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) + 0.05% sodium fluoride (NaF) in an alcohol-free base
Number of subjects: 188
Study 22403975 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash containing 0.05% NaF in an alcohol-free base
Number of subjects: 188
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 channel compression
Number of subjects: 20
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 channels compression
Number of subjects: 20
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 channels compression
Number of subjects: 20
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 channels compression
Number of subjects: 20
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 channels compression
Number of subjects: 20
Study 18664702 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing channel number
Number of subjects: 20
Study 16533356 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) and zinc sulphate (66 mg/day)
Number of subjects: 87
Study 16533356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 12713766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus pravastatin (pooled doses)
Number of subjects: 538
Study 12713766 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone (pooled doses)
Number of subjects: 538
Study 12713766 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 538
Study 11239753 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors shown patient questionnaires
Number of subjects: 265
Study 11239753 — intervention group
Group type: COMPARATOR
Intervention: Doctors not shown patient questionnaires
Number of subjects: 265
Study 9691865 — intervention group
Group type: COMPARATOR
Intervention: Magill position
Number of subjects: 20
Study 9691865 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual in-line position
Number of subjects: 20
Study 7828254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin fibreoptic laryngoscope (size 1.8 mm OD)
Number of subjects: 40
Study 7828254 — intervention group
Group type: COMPARATOR
Intervention: Rigid laryngoscope
Number of subjects: 40
Study 7828254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 3411312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor A
Number of subjects: 61
Study 3411312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor B
Number of subjects: 61
Study 31511193 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 1845
Study 31511193 — intervention group
Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 1845
Study 31395420 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP‐2/H (hydroxyapatite soaked with bone morphogenetic protein 2)
Number of subjects: 25
Study 31395420 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine xenograft
Number of subjects: 25
Study 29095180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vapocoolant spray
Number of subjects: 72
Study 29095180 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 72
Study 25674830 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-based group counseling (MBGC)
Number of subjects: 26
Study 25674830 — intervention group
Group type: COMPARATOR
Intervention: Control bereavement support group
Number of subjects: 26
Study 23751021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonischemic etiology
Number of subjects: 741
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: High trajectories of substance initiation
Number of subjects: 2931
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: High aggression trajectory
Number of subjects: 2931
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectories of delinquency
Number of subjects: 2931
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use trajectories
Number of subjects: 2931
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 2931
Study 21274853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic/racial differences
Number of subjects: 2931
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of lung cancer
Number of subjects: 1946
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Father's history of lung cancer
Number of subjects: 1946
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's history of lung cancer
Number of subjects: 1946
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling's history of lung cancer
Number of subjects: 1946
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of chronic bronchitis
Number of subjects: 1946
Study 19350630 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of pneumonia
Number of subjects: 1946
Study 17054743 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (AP)
Number of subjects: 255
Study 17054743 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 255
Study 15378867 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 cm distal stimulation technique
Number of subjects: 36
Study 15378867 — intervention group
Group type: COMPARATOR
Intervention: 3.5 cm distal stimulation technique
Number of subjects: 36
Study 10982248 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sucrose 200 mg intravenously twice weekly
Number of subjects: 12
Study 10982248 — intervention group
Group type: COMPARATOR
Intervention: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sulfate 160 mg/day orally
Number of subjects: 12
Study 9283863 — intervention group
Group type: EXPERIMENTAL
Intervention: Levsin
Number of subjects: 308
Study 9283863 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 308
Study 29925680 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Treatment (NPT) applied on the sutured wound for one week postoperatively
Number of subjects: 91
Study 29925680 — intervention group
Group type: COMPARATOR
Intervention: Traditional dressings used postoperatively
Number of subjects: 91
Study 27255080 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-adherence tool intervention
Number of subjects: 25
Study 27255080 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 25
Study 27255080 — intervention group
Group type: COMPARATOR
Intervention: Baseline questionnaire (Control)
Number of subjects: 25
Study 27255080 — intervention group
Group type: COMPARATOR
Intervention: Medication-adherence assessment (Control)
Number of subjects: 25
Study 27255080 — intervention group
Group type: COMPARATOR
Intervention: Implementation of the tool (Control)
Number of subjects: 25
Study 24292489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamponade
Number of subjects: 100
Study 24292489 — intervention group
Group type: COMPARATOR
Intervention: No Tamponade
Number of subjects: 100
Study 21772309 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator
Number of subjects: 119
Study 19661244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d
Number of subjects: 65
Study 19661244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16451406 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam monotherapy
Number of subjects: 763
Study 16451406 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 763
Study 16451406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study 16451406 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 763
Study 15579793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15579793 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg FSH-CTP
Number of subjects: 55
Study 15579793 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg FSH-CTP
Number of subjects: 55
Study 15579793 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg FSH-CTP
Number of subjects: 55
Study 15579793 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg FSH-CTP
Number of subjects: 55
Study 11318079 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily with azithromycin
Number of subjects: 0
Study 11318079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily with azithromycin
Number of subjects: 0
Study 11318079 — intervention group
Group type: COMPARATOR
Intervention: All regimens (desloratadine and fexofenadine with and without azithromycin)
Number of subjects: 0
Study 9595647 — intervention group
Group type: EXPERIMENTAL
Intervention: COBE Spectra leukoreduction system (LRS)
Number of subjects: 89
Study 9595647 — intervention group
Group type: COMPARATOR
Intervention: Standard dual-needle separations
Number of subjects: 89
Study 7945475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX)
Number of subjects: 123
Study 2835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg once daily
Number of subjects: 21
Study 2835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21
Study 2835890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29274386 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural-lexical approach for auditing SNOMED CT using non-lattice subgraphs and lexical attributes.
Number of subjects: 200
Study 29274386 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of suggested missing IS-A relations by domain experts.
Number of subjects: 200
Study 28855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 1670
Study 28855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 1670
Study 28855173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1670
Study 26238278 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Critical Time Intervention (FCTI)
Number of subjects: 200
Study 26238278 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 23137168 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaginal self-sampling
Number of subjects: 3767
Study 21044669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of PCV-7
Number of subjects: 0
Study 21044669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of PCV-7
Number of subjects: 0
Study 21044669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of PCV-7
Number of subjects: 0
Study 21044669 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV-23
Number of subjects: 0
Study 21044669 — intervention group
Group type: COMPARATOR
Intervention: 0 doses of PCV-7 (unvaccinated group)
Number of subjects: 0
Study 18789766 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44 mcg subcutaneous three times per week)
Number of subjects: 764
Study 18789766 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (20 mg subcutaneous once per day)
Number of subjects: 764
Study 18789766 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 764
Study 18789766 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate
Number of subjects: 764
Study 16420462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 45
Study 16420462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15537482 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 694
Study 15537482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study 11333990 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity
Number of subjects: 522
Study 11333990 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 522
Study 9017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Stroop task
Number of subjects: 22
Study 9017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Stroop task with sadness-laden words
Number of subjects: 22
Study 8318242 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 28
Study 8318242 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 28
Study 3329530 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 526
Study 3329530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 31060522 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth ball use
Number of subjects: 512
Study 31060522 — intervention group
Group type: COMPARATOR
Intervention: Usual midwifery care
Number of subjects: 512
Study 29019365 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (22.5 g freeze-dried) twice daily for six weeks
Number of subjects: 0
Study 24365871 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring system (RMS) intervention for 3 months
Number of subjects: 21
Study 24365871 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions (control group)
Number of subjects: 21
Study 23506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25.6 ± 12.6 mg daily)
Number of subjects: 61
Study 23506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5.0 ± 2.4 mg daily)
Number of subjects: 61
Study 23506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5.0 ± 2.4 mg daily)
Number of subjects: 61
Study 22047610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education provided to weight loss trial participants
Number of subjects: 29
Study 22047610 — intervention group
Group type: COMPARATOR
Intervention: Control group not exposed to nutrition education
Number of subjects: 29
Study 22047610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 19619218 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of clinical information to carers as expected by patients and carers
Number of subjects: 321
Study 19619218 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of clinical information to carers as expected by physicians
Number of subjects: 321
Study 19619218 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of information updates as expected by carers
Number of subjects: 321
Study 19619218 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of information updates as expected by physicians
Number of subjects: 321
Study 17326998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound (TCD) measurements in CADASIL patients
Number of subjects: 6
Study 17326998 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age and sex matched)
Number of subjects: 6
Study 15602250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application before injections
Number of subjects: 24
Study 15602250 — intervention group
Group type: COMPARATOR
Intervention: No ice application (control)
Number of subjects: 24
Study 11740143 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 50
Study 11740143 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH (uFSH)
Number of subjects: 50
Study 9143864 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 38
Study 8430199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadopentetate dimeglumine
Number of subjects: 199
Study 8430199 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadopentetate dimeglumine
Number of subjects: 199
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antagonist dimethindene (Di) (0.1 mg/kg i.v.)
Number of subjects: 0
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-antagonist cimetidine (Ci) (5 mg/kg i.v.)
Number of subjects: 0
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimethindene and cimetidine (Di + Ci)
Number of subjects: 0
Study 3659227 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ci and Di
Number of subjects: 0
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (Ci) alone
Number of subjects: 0
Study 3659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene (Di) alone
Number of subjects: 0
Study 31137964 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (IPI-145)
Number of subjects: 0
Study 31137964 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0
Study 29024821 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Feedback (OF) technology
Number of subjects: 594
Study 29024821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OF technology)
Number of subjects: 594
Study 25872465 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐cornered laterally rotated flap (flap 1)
Number of subjects: 28
Study 25872465 — intervention group
Group type: COMPARATOR
Intervention: Envelope flap with secondary closure (flap 2)
Number of subjects: 28
Study 24001154 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (100 mg) plus GBE (80 mg)
Number of subjects: 34
Study 24001154 — intervention group
Group type: COMPARATOR
Intervention: cilostazol (100 mg) plus placebo
Number of subjects: 34
Study 20934771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (70-100 mg/procedure)
Number of subjects: 61
Study 20934771 — intervention group
Group type: COMPARATOR
Intervention: Midazolam sedation (3-6 mg/procedure)
Number of subjects: 61
Study 20934771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 61
Study 20934771 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no sedation)
Number of subjects: 61
Study 19559158 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review on treatment options for osteoporosis in IBD; specific interventions not detailed.
Number of subjects: 0